MBX Biosciences Announced Results From Its Phase 1 Single Ascending Dose And Multiple Ascending Dose Trial Of MBX 1416 In Healthy Adult Volunteers. The Company Is Developing MBX 1416 For Post-bariatric Hypoglycemia

Benzinga · 01/07 12:06
  • Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025
  • Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile
  • Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing